Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis.

CONCLUSIONS: Maintenance treatment by rituximab could be cost-effective for preventing relapses in patients with AAV.
PMID: 31162031 [PubMed - in process]

Source: Clinical and Experimental Rheumatology - June 6, 2019 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research